Stockscreener 앱 받기
31.43
3.15%
0.9242
Moderna Inc 주식(MRNA)의 최신 뉴스
Moderna (MRNA) Valuation Check as CEPI Backs Phase 3 H5 Bird Flu Vaccine with $54.3 Million Funding - Yahoo Finance
Moderna, Inc. (MRNA): A Bull Case Theory - Finviz
Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullbac - GuruFocus
Why Moderna (MRNA) Stock Is Up Today - Finviz
After HHS walks away from mRNA vaccine research, Moderna finds $54M lifeline - Scripps News
Moderna gets $54.3 million investment for bird flu vaccine - upi.com
Moderna secures up to $54.3 million funding for bird flu vaccine from global coalition - Reuters
Moderna gets funding for H5 pandemic influenza vaccine - Yahoo Finance
Moderna Gets Bird Flu Shot Funding After HHS Ends Contract - Bloomberg.com
Moderna Scores $54 Million From CEPI To Fund Bird Flu Vaccine - BioSpace
Moderna (MRNA) Advances with $54.3M Boost for H5 Flu Vaccine Tri - GuruFocus
Moderna (MRNA) Secures $54.3M Funding for Bird Flu Vaccine Trial - GuruFocus
Biotech Leader Afeyan Warns That ‘Scientific Method Is Under Attack’ In The US - Citeline News & Insights
Moderna Gets Funding for Bird Flu Shot After HHS Ends Contract - Bloomberg.com
Discipline and Rules-Based Execution in MRNA Response - news.stocktradersdaily.com
University of TorontoU of T and Moderna partner to advance vaccine science, cancer treatment and AI-driven therapeutics - Education News Canada
Key facts: French study confirms Moderna vaccine reduces COVID-19 deaths; Moderna to present at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Moderna (MRNA) Stock Trades Up, Here Is Why - Finviz
Moderna (NASDAQ:MRNA) Trading 5.3% HigherShould You Buy? - MarketBeat
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Nanobiotechnology Market to Hit USD 420.2 Billion by 2034, Fueled by 2025 Traffic Growth and Strategic Material & Product Innovations - GlobeNewswire Inc.
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference - Fresno Bee
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike - Yahoo Finance
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma - Erie Times-News
Moderna (MRNA) Is Up 5.9% After EMA Backs New mNEXSPIKE VaccineHas The Bull Case Changed? - Yahoo Finance
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - Coshocton Tribune
FDA Commissioner Makary says 'black box' warning not coming to COVID vaccines - Seeking Alpha
Moderna Options Trading: A Deep Dive into Market Sentiment - Benzinga
Moderna (MRNA) Sees Mild Bearish Sentiment Among Option Traders - GuruFocus
Insider Selling: Moderna (NASDAQ:MRNA) Director Sells 23,853 Shares of Stock - MarketBeat
Noubar Afeyan, Moderna director, sells $703k in MRNA stock - Investing.com
Chmn Afeyan Sells 23,853 ($703.3K) Of Moderna Inc [MRNA] - TradingView — Track All Markets
Moderna’s new COVID vaccine receives positive CHMP opinion By Investing.com - Investing.com India
Moderna (MRNA) Gains European Approval Nod for New COVID Vaccine - GuruFocus
Moderna’s new COVID vaccine receives positive CHMP opinion - Investing.com
Moderna (NASDAQ: MRNA) COVID shot mNEXSPIKE backed by EMA panel for EU nod - Stock Titan
Big COVID-19 Vaccine Update: Pfizer, Moderna Nearing Finish Line - cbn.com
Moderna on track to extend gains for the seventh straight trading day - MSN
Telemark Asset Management, LLC's Moderna Inc(MRNA) Holding History - GuruFocus
Moderna to Host Investor Event – Analyst Day - York Dispatch
Bellevue Group AG Has $34.18 Million Stock Position in Moderna, Inc. $MRNA - MarketBeat
Banque Transatlantique SA Cuts Position in Moderna, Inc. $MRNA - MarketBeat
PayPal, SoundHound, Moderna, Devon, Bristol-Myers: Trending by Analysts - TipRanks
Jefferies Initiates Coverage of Moderna (MRNA) with Hold Recommendation - Nasdaq
Moderna (NASDAQ:MRNA) Director Sells $13,910.40 in Stock - MarketBeat
Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says - Proactive financial news
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Morningstar
ImmunityBio, Moderna among winners of EU drug recommendations this week - Seeking Alpha
EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike - TradingView
Moderna (MRNA) Faces Rising Short Interest Amid Sector Challenges - GuruFocus
Morgan Stanley Adjusts Moderna Price Target to $28 From $30, Maintains Equalweight Rating - marketscreener.com
MRNA: Jefferies Initiates Coverage with Hold Rating and $30 PT | - GuruFocus
Jefferies Initiates Coverage on Moderna With Hold Rating, $30 Price Target - marketscreener.com
Moderna signs deal worth up to $503m with Nanexa - Pharmaceutical Technology
0.50%
0.15%
자본화:
|
볼륨(24시간):